FIELD: biotechnology.
SUBSTANCE: disclosed are antibodies or antigen-binding fragments thereof, which specifically bind to C5, as well as pharmaceutical compositions containing said antibodies or fragments thereof. Also disclosed are nucleic acids coding said antibodies or fragments thereof, expression vectors and host cells containing said nucleic acids, a method of producing antibodies.
EFFECT: disclosed antibodies can be used to treat, prevent and/or diagnose disorders, such as complement-mediated disorders.
48 cl, 4 dwg, 6 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY MOLECULES AGAINST APRIL AND APPLICATIONS THEREOF | 2016 |
|
RU2793755C2 |
| NATRIURETIC PEPTIDE RECEPTOR-1 ANTIBODIES AND METHODS OF USE THEREOF | 2020 |
|
RU2827871C2 |
| ANTIBODIES TO ICOS | 2016 |
|
RU2742241C2 |
| ANTIBODIES TO ENTPD2, TYPES OF COMBINATION THERAPY AND METHODS FOR USING ANTIBODIES AND TYPES OF COMBINATION THERAPY | 2019 |
|
RU2790991C2 |
| CORRESPONDING TARGET FOR TREATING FIBROSING DISEASES AND USE THEREOF | 2021 |
|
RU2830698C1 |
| TIGIT ANTIBODIES AND USE THEREOF | 2020 |
|
RU2827445C2 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
| FGF21 MIMETIC ANTIBODIES AND THEIR APPLICATION METHODS | 2018 |
|
RU2774368C2 |
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
| 5-BROMO-2,6-DI - (1H-PYRAZOL-1-YL)PYRIMIDINE-4-AMINE FOR USE IN CANCER TREATMENT | 2016 |
|
RU2745560C2 |
